Transport and Biotransformation of Gliclazide and the Effect of Deoxycholic Acid in a Probiotic Bacteria Model

Introduction: Inter-individual differences in gut microflora composition may affect drug metabolism and overall therapeutic response. Gliclazide is a drug characterized by large inter-individual differences in therapeutic response; however, the causes of these differences are not fully explained and may be the outcome of microbial biotransformation. Recently, great attention has been paid to studies on bile acid (BA) interactions with gut microflora and the role of BAs in the modification of drug transport through biological membranes. The Aim: Considering the assumption of gliclazide–probiotic–BAs interactions, the aim of the study was to investigate the transport and biotransformation of gliclazide in probiotic bacteria, as well as the effects of deoxycholic acid (DCA) on gliclazide transport into bacterial cells. Materials and Methods: Probiotics were incubated with gliclazide with or without DCA for 24 h at 37°C. The intracellular and extracellular concentrations of gliclazide were determined at seven time points by high-performance liquid chromatography. Gliclazide biotransformation by the enzymatic activity of probiotic bacteria was examined using appropriate software packages. Results: During the 24 h incubation with probiotic bacteria, significantly lower extracellular concentrations of gliclazide were observed at all time points compared to controls, while in the group with DCA, the decrease in concentration was noticed only at 24 h. The total concentration of gliclazide throughout the whole period was significantly lower compared to control. Proposed pathways of gliclazide biotransformation by probiotic bacteria involve reactions of hydrolysis and hydroxylation. Conclusion: Based on the results obtained, it can be concluded that there are interactions of gliclazide–probiotics–DCA, at both the level of active and passive transport into the cells, and at the level of drug biotransformation by enzymatic activity of probiotic bacteria. The effect of these interactions on the final therapeutic response of gliclazide should be further studied and confirmed in in vivo conditions.

[1]  N. Pavlović,et al.  Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome , 2018, Front. Pharmacol..

[2]  N. Pavlović,et al.  Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles , 2018, Front. Pharmacol..

[3]  Junmin Zhang,et al.  Gut microbiota modulates drug pharmacokinetics , 2018, Drug metabolism reviews.

[4]  N. Pavlović,et al.  Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics , 2018, European Journal of Drug Metabolism and Pharmacokinetics.

[5]  M. Choi,et al.  The role of gut microbiota in the pharmacokinetics of antihypertensive drugs , 2018, Pharmacological research.

[6]  Han-Seung Shin,et al.  Benefaction of probiotics for human health: A review , 2018, Journal of food and drug analysis.

[7]  S. Fukiya,et al.  Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents , 2017, Journal of Lipid Research.

[8]  S. Vukmirović,et al.  High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect , 2017, European Journal of Drug Metabolism and Pharmacokinetics.

[9]  N. Juge,et al.  Introduction to the human gut microbiota , 2017, The Biochemical journal.

[10]  I. Thiele,et al.  Gut microbiota functions: metabolism of nutrients and other food components , 2017, European Journal of Nutrition.

[11]  K. Nikolić,et al.  The influence of bile salts on the distribution of simvastatin in the octanol/buffer system , 2016, Drug development and industrial pharmacy.

[12]  A. Singh,et al.  Is gliclazide a sulfonylurea with difference? A review in 2016 , 2016, Expert review of clinical pharmacology.

[13]  G. Cresci,et al.  Gut Microbiome: What We Do and Don't Know. , 2015, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[14]  C. Klaassen,et al.  Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids , 2015, Drug Metabolism and Disposition.

[15]  Kavita R Pandey,et al.  Probiotics, prebiotics and synbiotics- a review , 2015, Journal of Food Science and Technology.

[16]  V. Young,et al.  The gut microbiome in health and in disease , 2015, Current opinion in gastroenterology.

[17]  H. Yoo,et al.  Gut Microbiota-Mediated Drug Interactions between Lovastatin and Antibiotics , 2014, Drug Metabolism and Disposition.

[18]  N. Pavlović,et al.  Application of bile acids in drug formulation and delivery , 2013 .

[19]  H. Al‐Salami,et al.  Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat , 2013, Journal of diabetes research.

[20]  M. Fromm,et al.  Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs , 2011, Pharmaceutics.

[21]  H. Gwak,et al.  Effects of bile salts on the lovastatin pharmacokinetics following oral administration to rats , 2011, Drug delivery.

[22]  Ola Spjuth,et al.  Use of historic metabolic biotransformation data as a means of anticipating metabolic sites using MetaPrint2D and Bioclipse , 2010, BMC Bioinformatics.

[23]  P. Murthy,et al.  Physicochemical Properties of Solid Dispersions of Gliclazide in Polyvinylpyrrolidone K90 , 2009, AAPS PharmSciTech.

[24]  Abdul W Basit,et al.  The gastrointestinal microbiota as a site for the biotransformation of drugs. , 2008, International journal of pharmaceutics.

[25]  I. Tucker,et al.  Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats , 2008, Archives of drug information.

[26]  B. Natalini,et al.  Correlation between CMC and chromatographic index: simple and effective evaluation of the hydrophobic/hydrophilic balance of bile acids , 2007, Analytical and bioanalytical chemistry.

[27]  N. Dikmen,et al.  Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with beta-cyclodextrin. , 2000, Pharmaceutica acta Helvetiae.

[28]  J. Beilby,et al.  Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. , 2000, British journal of clinical pharmacology.

[29]  D. Kingston,et al.  Anaerobic metabolism of 2-amino-3-methyl-3H-imidazo[4,5-f]quinoline (IQ) by human fecal flora. , 1987, Mutation research.

[30]  K. Kobayashi,et al.  Pharmacokinetics of gliclazide in healthy and diabetic subjects. , 1984, Journal of pharmaceutical sciences.

[31]  V. Oliverio,et al.  Antibiotics Alter Methotrexate Metabolism and Excretion , 1969, Science.

[32]  Jeremy K Nicholson,et al.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity. , 2017, Translational research : the journal of laboratory and clinical medicine.

[33]  N. Pavlović,et al.  Docking-based preliminary study on the interactions of bile acids with drugs at the transporter level in intestinal bacteria. , 2016, European review for medical and pharmacological sciences.

[34]  M. Mikov,et al.  The Influence of Intestinal Tract and Probiotics on the Fate of Orally Administered Drugs. , 2014, Current issues in molecular biology.

[35]  V. Anuța,et al.  STUDY OF THE INFLUENCE OF BILE SALTS AND LECITHIN ON DISTRIBUTION OF KETOCONAZOLE BETWEEN PLASMA AND METHYLENE CHLORIDE , 2012 .

[36]  F. Kiran,et al.  Comparison of three methods for determination of protein concentration in lactic acid bacteria for proteomics studies , 2012 .

[37]  P. Kovacs,et al.  Therapy with oral antidiabetic drugs: applied pharmacogenetics , 2011 .

[38]  K. Yoshida,et al.  The metabolism of gliclazide in man. , 1985, Xenobiotica; the fate of foreign compounds in biological systems.